SS-31, also called elamipretide or MTP-131, is a small peptide that acts within , the cell’s energy-producing structures. It interacts with a specialized fat in their inner membrane. Picture a power plant whose equipment depends on the organization of its internal workspace: this peptide is studied for helping support that organization and function. Its specific medical evidence should be distinguished from broader claims about energy or aging.
SOURCE REFERENCE
Mixing and dose chart
Current aggregated data suggests the following information:
Each row shows a separate source example for SS-31 (MTP-131).
Bacteriostatic water is a source assumption. Amounts and schedules are not independently verified or personal medical advice. Consult a qualified clinician.
Peptide per Vial (mg)
BAC water
Dose
U-100 syringe
Frequency
10 mg
2 mL
0.4 mg
8 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4 week off period.
10 mg
3 mL
0.4 mg
12 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4 week off period.
Forzinity received accelerated FDA approval in 2025 for improving muscle strength in Barth syndrome patients weighing at least 30 kg. This narrow indication does not establish general anti-aging benefits. [34, 35]
Mechanism, evidence and interpretation
It binds , a specialized fat in the inner mitochondrial membrane. This interaction is intended to support membrane organization and mitochondrial function.
Forzinity received accelerated FDA approval in 2025 for improving muscle strength in Barth syndrome patients weighing at least 30 kg. This narrow indication does not establish general anti-aging benefits. [34, 35]
The current label describes localization to the inner mitochondrial membrane and binding to . Accelerated approval rests on knee extensor strength, an intermediate endpoint; confirmatory evidence remains important. This should not be presented as proof of general rejuvenation. [34, 35]
4 mL
0.37 mg
5 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4 week off period.
30 mg
5 mL
0.42 mg
7 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4 week off period.
50 mg
5 mL
0.4 mg
4 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4week off period.
50 mg
7 mL
0.42 mg
6 UNITS
Once daily 5 days per week for 4 weeks, followed by a 4week off period.
THE DOSING REFERENCE
Dosing instructions
Amounts, schedules, and preparation - organized and summarized from current aggregated data
SS-31 is a development name for elamipretide, a synthetic four-amino-acid peptide also investigated under other development codes. It was designed to influence mitochondrial function through interactions associated with the inner mitochondrial membrane. The molecule is different from MOTS-C, a peptide associated with , and from NAD+, a metabolic . A shared mitochondrial theme does not imply a shared mechanism.
Elamipretide is the active ingredient in the prescription product Forzinity. That product has a specific approved use in Barth syndrome, a rare genetic disorder involving mitochondrial biology. The research code SS-31 and the approved product name should be connected accurately, while preserving the difference between a regulated and a research vial. Product quality, route and instructions remain part of the evidence.
Cardiolipin and membrane organization
is a lipid concentrated in the inner mitochondrial membrane. The membrane supports proteins that transfer electrons and help create the conditions for production. Its structure and organization are important to energy processing. Elamipretide research focuses on interactions with this membrane environment, including cardiolipin-related biology. This is a more specific mechanism than the general statement that the compound increases energy.
Changing a membrane interaction does not automatically establish an improvement in every symptom or disease associated with . Different disorders can involve different defects, tissues and stages of damage. Cell experiments may demonstrate a biochemical effect, while a must determine whether that effect improves a relevant patient outcome. The distinction is particularly important when a mitochondria-related mechanism is used to advertise endurance, cognitive enhancement or general rejuvenation.
FDA granted accelerated approval to Forzinity in September 2025 for improving muscle strength in people with Barth syndrome who weigh at least 30 kilograms. The approval is specific to that disorder and product. Accelerated approval also involves continuing evidence requirements; it should not be described as a blanket confirmation of every proposed elamipretide use. The trial program was small, reflecting the rarity of the condition, and its design needs to be understood when interpreting the findings.
Barth syndrome involves a particular biological defect related to remodeling. That makes it different from ordinary tiredness, healthy aging or a broad wellness goal. A benefit identified in that setting cannot simply be transferred to people without the disorder. Research in other mitochondrial conditions has asked separate questions and needs to be interpreted through those individual studies. The approved indication is evidence of a defined clinical use, not of universal mitochondrial enhancement.
An older source may describe SS-31 as entirely unapproved, while a newer product label documents the narrow Forzinity indication. Both the date and specificity matter. The accurate article should update the clinical history without implying that all SS-31 preparations now have that approval. The current prescribing information includes product-specific administration and safety details, which are different from an archived research schedule.
Compare elamipretide with MOTS-C to distinguish a membrane-directed molecule from a mitochondrial-associated signaling peptide. Compare it with NAD+ to distinguish a drug mechanism from essential metabolic chemistry. These comparisons show why the word mitochondrial alone cannot establish action, evidence level or suitability. The exact compound, disease and measured outcome should lead the interpretation.
Energy balance and metabolic signaling
Metabolism describes the chemical work that keeps cells alive. Nutrients are broken down, converted into usable energy, stored or used to build other molecules. Hormones help coordinate this work across the brain, gut, pancreas, liver, muscle and fat tissue. A change in one pathway can affect several organs at once. This is why a compound described as metabolic may influence appetite, blood glucose, fuel use or cellular stress without necessarily doing all of these things equally well.
Energy balance still matters, but its regulation is more complex than a voluntary choice to eat less. Signals from the gut and brain influence hunger, fullness and food reward. helps coordinate nutrient storage and use. supports glucose availability, especially when food is not arriving. Fat tissue stores energy and also sends hormonal signals. process fuels inside cells. An intervention can work mainly through appetite, through glucose control, through cellular chemistry, or through several of these routes together.
These mechanisms must be kept separate when comparing compounds. Semaglutide and tirzepatide act on defined hormone and have large programs. MOTS-C is discussed through a different experimental pathway. Claims about fat loss need to be evaluated against the evidence for each compound. A substance that changes a cell's handling of energy has not necessarily demonstrated lasting weight reduction in people.
Researchers also need to decide what improvement means. Lower body weight, reduced , improved blood glucose and fewer cardiovascular events are distinct outcomes. A trial may establish one without establishing the others. Weight change can include both fat and lean tissue, and includes water as well as muscle. The amount of change, how long it lasts, treatment discontinuations and adverse effects all affect the practical interpretation. Comparing headline percentages from unrelated studies can be misleading because participants, support programs, follow-up periods and analysis methods differ. The most useful evidence connects a clearly identified product to a clearly measured outcome in a clearly described group of people.
How to read the research and dosing record
The dosing record above and this article serve different purposes. The record preserves source amounts and schedules. The article explains identity, biology and evidence. An archived schedule is not a clinically validated prescription, and a calculation cannot decide whether a compound is suitable for a person. Keep the exact molecule, , route and strength attached to any research claim. Do not treat an animal experiment as a human dosing instruction or transfer a prescription product's instructions to a different vial.
When checking a paper, first identify who or what was studied. Then check the comparison group, the measured outcome, the length of follow-up and reported adverse effects. A laboratory marker and a patient benefit are different endpoints. Small exploratory studies can help generate a hypothesis, while larger controlled studies can test it more reliably. Internal compound links provide comparisons, and the dotted terms open short definitions with links to the site's glossary. The source links below let you check the original context rather than relying on a headline.
Key facts
SOURCE DATA
Molecular formula
—
Molecular weight
—
CAS number
—
Sequence
—
Half-life
Not established for a general human-use regimen in the reviewed evidence.
Source mass amounts and schedules are retained. Reviewed syringe conversions use the stated preparation; unresolved conversions are labeled unavailable. Not personal medical advice. Consult a qualified clinician for decisions about personal use.
Calculated doses are derived from the source UNITS and assume added liquid equals final volume. U-100 UNITS measure volume, not drug activity. Source UNITS may be rounded or differ from an explicit dose; see the detailed source protocol below.
Source reference for research and education. Not personal medical advice. Amounts and clinical suitability are not independently verified. Conversion checks are labeled below.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source review note
Source-reported quantities and schedules are educational comparisons, not verified administration instructions. Route, diluent compatibility, vial capacity, final volume and clinical suitability are unverified. Added liquid is assumed to equal final volume only for arithmetic. U-100 UNITS measure volume; drug activity IU is a separate unit.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Source-specific review note
The supplied schedule ends “followed by a 4.” Its missing duration and unit remain unresolved; no washout duration is inferred.
Research discussion 0
Share a source, ask a question, or add context. Every comment is reviewed before it appears publicly.
Explore the peptide forum → for dedicated threads and nested conversations.
Save your research and join the conversation.
Sign in to comment